Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporin A.

E H Page, D M Wexler, L C Guenther

    Journal of the American Academy of Dermatology
    |May 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Cyclosporin A, an immunosuppressive drug, shows promise in treating various skin conditions like psoriasis and autoimmune diseases. Dermatologists should be aware of its benefits and potential side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.

    The British journal of dermatology·2020
    Same author

    Psoriasis patients' preference for an aerosol foam topical formulation.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2018
    Same author

    Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).

    Skin therapy letter·2009
    Same author

    Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay.

    Occupational and environmental medicine·2004
    Same author

    Visual and ocular changes associated with exposure to two tertiary amines.

    Occupational and environmental medicine·2002
    Same author

    Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging.

    Skin therapy letter·2002
    Same journal

    Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Safety of Biologic Therapy in Psoriasis Patients With Malignancy.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Letter from the Editor: Glucagon-Like Peptide-1 (GLP-1) agonists in dermatology.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Rethinking the Occipital Scalp as a Control in Advanced Androgenetic Alopecia.

    Journal of the American Academy of Dermatology·2026
    Same journal

    Parallel-Polarized Dermoscopy for Acral Parallel Pattern Analysis.

    Journal of the American Academy of Dermatology·2026
    See all related articles

    Area of Science:

    • Immunology
    • Dermatology
    • Pharmacology

    Background:

    • Cyclosporin A is a novel immunosuppressive agent.
    • It selectively targets T helper cells without causing bone marrow suppression.
    • Primary applications include preventing organ transplant rejection and graft-versus-host disease.

    Purpose of the Study:

    • To review the dermatologic applications of Cyclosporin A.
    • To inform dermatologists about its potential benefits and side effects.

    Main Methods:

    • Literature review of studies on Cyclosporin A in dermatology.
    • Analysis of its efficacy in various skin disorders.
    • Examination of reported dermatologic side effects.

    Main Results:

    Related Experiment Videos

    • Cyclosporin A demonstrates potential benefits for psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's disease, and collagen vascular disorders.
    • Dermatologic side effects are associated with its use.

    Conclusions:

    • Cyclosporin A holds significant potential for dermatologic treatment.
    • Familiarity with its therapeutic uses and adverse effects is crucial for dermatologists.